Allergan Investor Claims Over Botox Penalty Thrown Out

Allergan Inc. directors won’t have to face investor lawsuits seeking to hold them responsible for a $600 million penalty the company paid over illegal marketing of the wrinkle-smoother Botox, the Delaware Supreme Court said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.